Trials / Recruiting
RecruitingNCT06072430
A Phase III, Open Label, Randomized, Controlled Study of VBI-S in the Treatment of Hypovolemia in Patients With Septic Shock (VBI-S-02)
A Phase III, Open Label, Randomized, Controlled Study of VBI-S in the Treatment of Hypovolemia in Patients With Septic Shock
- Status
- Recruiting
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 46 (estimated)
- Sponsor
- Vivacelle Bio · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study is being conducted to evaluate the safety and effectiveness of VBI-S in elevating the blood pressure of septic shock patients with absolute or relative hypovolemia.
Detailed description
PURPOSE OF THE STUDY This study is being conducted to evaluate the safety and effectiveness of VBI-S in elevating the blood pressure of septic shock patients with absolute or relative hypovolemia. STUDY TREATMENT Sepsis is a serious condition resulting from the presence of harmful microorganisms in the blood or other tissues and the body's response to their presence, leading to the malfunctioning of various organs. When hypotension due to sepsis cannot be reversed with the infusion of fluids the patient is in a state of septic shock. Septic shock is therefore an acute medical emergency and delayed therapy can lead to organ injury. VBI-S is intended to raise blood pressure in patients with septic shock. Randomization and blinding: This is a randomized, controlled, open-label study and blinding is not applicable to this study. Data Safety Monitoring Board: A Data Safety Monitoring Board (DSMB) will review the study data.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | VBI-S | VBI-S is made of small particles of specific lipids called micelles and liposomes for the treatment of hypotension. |
Timeline
- Start date
- 2024-08-06
- Primary completion
- 2025-12-01
- Completion
- 2025-12-01
- First posted
- 2023-10-10
- Last updated
- 2025-04-04
Locations
6 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06072430. Inclusion in this directory is not an endorsement.